# The effect of a low FODMAP diet on luminal microbiota, fermentation and symptoms

Submission date Recruitment status Prospectively registered 22/01/2010 No longer recruiting [ ] Protocol [ ] Statistical analysis plan Registration date Overall study status 08/03/2010 Completed [X] Results Individual participant data **Last Edited** Condition category 14/11/2013 **Digestive System** 

#### Plain English summary of protocol

Not provided at time of registration

# **Contact information**

#### Type(s)

Scientific

#### Contact name

Dr Kevin Whelan

#### Contact details

4.06 Franklin Wilkins Building King's College London 150 Stamford St London United Kingdom SE1 9NH

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

# Study information

#### Scientific Title

The effect of a low FODMAP diet on luminal microbiota, fermentation and symptoms: A randomised controlled trial

#### **Study objectives**

H0: there will be no significant difference in the concentration of faecal bifidobacteria in patients with Irritable Bowel Syndrome (IBS) following a low FODMAP diet (intervention) compared with those following a normal diet (control) for four weeks.

H1: there will be a significant difference in the concentration of faecal bifidobacteria in patients with IBS following a low Fermentable Oligo-, Di-, and Monosaccharides and Polyol (FODMAP) diet (intervention) compared with those following a normal diet (control) for four weeks.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Guy's Research Ethics Committee, 11/11/2009, ref: 09/H0804/89

#### Study design

Randomised controlled parallel group trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Other

#### Study type(s)

Treatment

#### Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet.

#### Health condition(s) or problem(s) studied

Irritable bowel syndrome

#### **Interventions**

4-week low FODMAP diet compared to usual diet.

Patients in the intervention group will receive individualised dietary advice. A low FODMAP diet is a diet low in poorly absorbed fermentable carbohydrates. Patients will follow the diet for 4 weeks. The total duration of the study will be 5 weeks.

#### Intervention Type

Other

#### Phase

#### Primary outcome measure

To assess the effect of a low FODMAP diet on faecal microbiota in patients with IBS. Faecal samples will be collected at baseline and at 4 weeks.

#### Secondary outcome measures

- 1. To assess the effect of a low FODMAP diet on faecal Short Chain Fatty Acid (SCFA), pH and faecal water in patients with IBS.
- 2. To assess the effect of a low FODMAP diet on symptoms in patients with IBS.
- 3. To assess the effect of a low FODMAP diet on stool consistency and frequency in patients with IBS.
- 4. To assess the nutritional adequacy of a low FODMAP diet in patients with IBS.
- 5. To assess the acceptability of a low FODMAP diet in IBS patients.
- 6. Weight and height.

Outcomes will be assessed at baseline and at 4 weeks. Patients will keep a symptom diary and diet diary, and 2 questionnaires will be used to assess nutritional adequacy, FODMAP intake and diet acceptability.

#### Overall study start date

01/02/2010

#### Completion date

31/12/2010

# **Eligibility**

#### Key inclusion criteria

Patients will be recruited from Gastrointestinal and Dietetic Outpatient clinics at Guys and St Thomas NHS Foundation Trust, London, UK.

- 1. Adult patients aged 18-65 years
- 2. Identified as having IBS based on Rome III criteria
- 3. Symptoms including bloating and/or diarrhoea

#### Participant type(s)

Patient

#### Age group

Adult

#### Lower age limit

18 Years

#### Upper age limit

65 Years

#### Sex

Both

#### Target number of participants

#### Key exclusion criteria

- 1. Patients with any other gastrointestinal disease or gastrointestinal surgery
- 2. Patients whose major IBS symptom is constipation
- 3. Patients receiving lactulose or any other probiotic or prebiotic substances in the four weeks prior to the study
- 4. Patients who have taken antibiotics in the 4 weeks prior to the study
- 5. Patients who have received bowel preparation for investigative procedures in the 4 weeks prior to the study
- 6. Patients with any other significant major organ disorders, including diabetes, psychiatric and current eating disorders
- 7. Patients who report to be pregnant or lactating
- 8. Patients who have had changes to IBS medications or dose in the 4 weeks prior to the study

#### Date of first enrolment

01/02/2010

#### Date of final enrolment

31/12/2010

#### Locations

#### Countries of recruitment

England

**United Kingdom** 

# Study participating centre 4.06 Franklin Wilkins Building

London United Kingdom SE1 9NH

# Sponsor information

#### Organisation

King's College London (UK)

#### Sponsor details

Hodgkin Building Guy's Campus Kings College London LondonSE1 1UL UNITED KINGDOM London England United Kingdom SE1 1UL

#### Sponsor type

University/education

#### **ROR**

https://ror.org/0220mzb33

# Funder(s)

#### Funder type

University/education

#### Funder Name

King's College London (UK)

# **Results and Publications**

#### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration  $% \left( 1\right) =\left( 1\right) \left( 1\right) \left($ 

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2012		Yes	No